Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 1:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 85 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: certolizumab pegol Clear all
Not listed Phase 4 Interventional

Optimizing Cimzia in Crohn's Patients

NCT01024647
View directory record Official record
Conditions
Crohn's Disease
Interventions
certolizumab pegol
Biological
Lead sponsor
Atlanta Gastroenterology Associates
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 4, 2012 · Synced Sep 10, 2026, 1:42 PM EDT
Completed Phase 3 Interventional Results available

A follow-on Safety Study in Subjects With Crohn's Disease Who Have Previously Been Withdrawn From the Double-blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425] Due to an Exacerbation of Crohn's Disease

NCT00160706
View directory record Official record
Conditions
Crohn's Disease
Interventions
Certolizumab Pegol (CDP870)
Biological
Lead sponsor
UCB Pharma SA
Industry
Eligibility
18 Years and older
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
41
States / cities
Birmingham, Alabama • Huntsville, Alabama • Little Rock, Arkansas + 37 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2018 · Synced Sep 10, 2026, 1:42 PM EDT
Completed Phase 3 Interventional Results available

Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS

NCT02552212
View directory record Official record
Conditions
Axial Spondyloarthritis, Nonradiographic Axial Spondyloarthritis, Nr-axSpA
Interventions
Certolizumab Pegol, Placebo
Biological · Other
Lead sponsor
UCB BIOSCIENCES GmbH
Industry
Eligibility
18 Years and older
Enrollment
317 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
36
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2022 · Synced Sep 10, 2026, 1:42 PM EDT
Completed Phase 4 Interventional

COVID-19 VaccinE Response in Rheumatology Patients

NCT05080218
View directory record Official record
Conditions
Rheumatoid Arthritis, Psoriatic Arthritis, Spondylarthritis
Interventions
Upadacitinib, Abatacept, Secukinumab, Tofacitinib, TNF Inhibitor, Canakinumab Injection, Baricitinib, Ixekizumab
Drug
Lead sponsor
Jeffrey Curtis
Other
Eligibility
18 Years to 85 Years
Enrollment
841 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
8
States / cities
Birmingham, Alabama • Hoover, Alabama • Phoenix, Arizona + 4 more
Source: ClinicalTrials.gov public record
Updated May 1, 2025 · Synced Sep 10, 2026, 1:42 PM EDT
Terminated No phase listed Observational

UCB Cimzia Pregnancy Follow-up Study

NCT02775656
View directory record Official record
Conditions
Rheumatoid Arthritis (RA), Crohn's Disease (CD), Psoriatic Arthritis (PsA), Axial Spondyloarthritis and Ankylosing Spondylitis
Interventions
Not listed
Lead sponsor
UCB BIOSCIENCES, Inc.
Industry
Eligibility
18 Years to 64 Years · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 21, 2021 · Synced Sep 10, 2026, 1:42 PM EDT
Not listed Phase 4 Interventional

Does Clinical Response Correlate With Serum Certolizumab Levels?

NCT02597829
View directory record Official record
Conditions
Crohn's Disease
Interventions
Certolizumab Pegol
Drug
Lead sponsor
Shafran Gastroenterology Center
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Winter Park, Florida
Source: ClinicalTrials.gov public record
Updated Nov 4, 2015 · Synced Sep 10, 2026, 1:42 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease

NCT00552344
View directory record Official record
Conditions
Crohn Disease
Interventions
Cimzia
Biological
Lead sponsor
UCB BIOSCIENCES GmbH
Industry
Eligibility
18 Years to 75 Years
Enrollment
403 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
20
States / cities
Lakewood, Colorado • Littleton, Colorado • New Port Richey, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2018 · Synced Sep 10, 2026, 1:42 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Pilot Study Evaluating the Efficacy of Certolizumab Pegol for Interstitial Cystitis

NCT02497976
View directory record Official record
Conditions
Cystitis, Interstitial
Interventions
Certolizumab pegol, Placebo
Biological · Drug
Lead sponsor
ICStudy, LLC
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Escondido, California
Source: ClinicalTrials.gov public record
Updated May 16, 2018 · Synced Sep 10, 2026, 1:42 PM EDT
Completed Phase 3 Interventional

The Effect of Certolizumab Pegol on MRI Synovitis and Bone Edema in Rheumatoid Arthritis Patients

NCT01213017
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
certolizumab pegol
Drug
Lead sponsor
Oklahoma Medical Research Foundation
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Aventura, Florida • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Dec 6, 2017 · Synced Sep 10, 2026, 1:42 PM EDT
Terminated Phase 4 Interventional Results available

Shingrix Vaccine in Patients With Moderate to Severe Ulcerative Colitis on Tofacitinib

NCT03591770
View directory record Official record
Conditions
Inflammatory Bowel Diseases
Interventions
SHINGRIX
Biological
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 20, 2025 · Synced Sep 10, 2026, 1:42 PM EDT
Completed Phase 3 Interventional Results available

Open Label Extension for Patients Coming From the Dosing Flexibility Study in Patients With Rheumatoid Arthritis (RA)

NCT00753454
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Certolizumab pegol
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
36
States / cities
Huntsville, Alabama • Paradise Valley, Arizona • Tucson, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Sep 10, 2026, 1:42 PM EDT
Completed Phase 3 Interventional Results available

Follow-up to Welcome Study C87042 [NCT00308581] Examining Certolizumab Pegol (CDP870) in Subjects With Crohn's Disease

NCT00333788
View directory record Official record
Conditions
Crohn's Disease
Interventions
Certolizumab pegol (CDP870)
Biological
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
19
States / cities
Gainesville, Florida • Atlanta, Georgia • Chicago, Illinois + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2018 · Synced Sep 10, 2026, 1:42 PM EDT
Completed Phase 4 Interventional

Biologic Abatement and Capturing Kids' Outcomes and Flare Frequency in Juvenile Spondyloarthritis

NCT04891640
View directory record Official record
Conditions
Juvenile Spondyloarthritis
Interventions
Standard TNFi Therapy, TNFi fixed longer dosing intervals, Stop TNFi treatment
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
8 Years to 21 Years
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
30
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Sep 10, 2026, 1:42 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO)

NCT02346240
View directory record Official record
Conditions
Psoriasis, Plaque Psoriasis
Interventions
Certolizumab Pegol, Etanercept, Placebo
Biological · Other
Lead sponsor
UCB Biopharma S.P.R.L.
Industry
Eligibility
18 Years and older
Enrollment
559 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
19
States / cities
Mobile, Alabama • Little Rock, Arkansas • Beverly Hills, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2021 · Synced Sep 10, 2026, 1:42 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Nipocalimab and Certolizumab Combination Therapy in Participants With Active Rheumatoid Arthritis

NCT06028438
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
Placebo, Nipocalimab, Certolizumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
10
States / cities
Phoenix, Arizona • Huntington Beach, California • Upland, California + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Sep 10, 2026, 1:42 PM EDT
Completed No phase listed Observational

Safety of TofAcitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA)- Cardiovascular Endpoints

NCT04772248
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Tofacitinib, TNF Inhibitor
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
105,711 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 1, 2022 · Synced Sep 10, 2026, 1:42 PM EDT
Completed Phase 3 Interventional Results available

A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis

NCT01519791
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Certolizumab Pegol, Placebo, Methotrexate
Biological · Other
Lead sponsor
UCB Pharma SA
Industry
Eligibility
18 Years and older
Enrollment
880 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
70
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 63 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 10, 2026, 1:42 PM EDT
Completed Phase 2 Interventional

Study of Cimzia for the Treatment of Ulcerative Colitis

NCT01090154
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Cimzia
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 75 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2021
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 13, 2021 · Synced Sep 10, 2026, 1:42 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Identifying Young Inflammatory Bowel Disease Patients at Risk for Herpes Zoster

NCT03553472
View directory record Official record
Conditions
Herpes Zoster, Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis
Interventions
Not listed
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
35 Years to 49 Years
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 18, 2019 · Synced Sep 10, 2026, 1:42 PM EDT
Completed Phase 3 Interventional Results available

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis

NCT00717236
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Certolizumab pegol (CZP), Placebo
Drug · Other
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
1,648 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
101
States / cities
Birmingham, Alabama • Montgomery, Alabama • Phoenix, Arizona + 98 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Sep 10, 2026, 1:42 PM EDT
Completed No phase listed Observational

Cytokines and Genes in Therapeutic Response in Crohn's Disease

NCT03266471
View directory record Official record
Conditions
Inflammatory Bowel Diseases
Interventions
Baseline blood sample, Baseline intestinal biopsies, Crohn's disease activity index (CDAI), Post treatment blood sample, Post treatment intestinal biopsies, Baseline stool sample, Post treatment stool sample
Diagnostic Test · Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
2
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 13, 2023 · Synced Sep 10, 2026, 1:42 PM EDT
Completed Phase 1 Interventional

Certolizumab in Combination With Chemotherapy for Patients With Stage IV Lung Adenocarcinomas

NCT02120807
View directory record Official record
Conditions
Stage IV Lung Adenocarcinoma
Interventions
Certolizumab, cisplatin, pemetrexed
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
6
States / cities
Basking Ridge, New Jersey • Commack, New York • Harrison, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2023 · Synced Sep 10, 2026, 1:42 PM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Effectiveness of Liquid Certolizumab Pegol in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis

NCT00160641
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Certolizumab Pegol
Biological
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
567 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
12
States / cities
Palm Desert, California • Pasadena, California • Santa Maria, California + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2020 · Synced Sep 10, 2026, 1:42 PM EDT
Suspended Phase 1 Interventional

Zr-89 Cimzia PET Imaging Rheumatoid Arthritis

NCT03546335
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
89Zr-DFO-CZP
Drug
Lead sponsor
Robert Flavell, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Sep 10, 2026, 1:42 PM EDT